<DOC>
	<DOCNO>NCT02503774</DOCNO>
	<brief_summary>The purpose study Evaluate Safety , Tolerability , Pharmacokinetics , Immunogenicity , Antitumor Activity MEDI9447 Alone Combination MEDI4736 Adult Subjects Select Advanced Solid Tumors</brief_summary>
	<brief_title>MEDI9447 Alone Combination With MEDI4736 Adult Subjects With Select Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Adult subject ; age ≥ 18 2 . Written sign informed consent must obtain 3 . Have histologic cytologic documentation solid tumor ◦ Must receive progressed , refractory , intolerant standard therapy appropriate specific tumor type . Depending tumor type , subject receive 5 prior line therapy recurrent metastatic disease include standard care investigational therapy 4 . Subjects must least 1 lesion measureable use RECIST guideline 5 . Subjects must consent provide archived tumor specimen tumor biopsy correlative biomarker study . 6 . All subject encourage consent provide pair pretreatment ontreatment tumor biopsy . 7 . In doseexpansion phase , subject encourage consent provide pair pretreatment ontreatment tumor biopsy 8 . Eastern Cooperative Oncology Group performance score 0 1 9 . In opinion investigator , likely complete ≥ 56 day treatment 10 . Adequate organ function determine : I.Absolute neutrophil count ≥ 1.5 × 109/L ( 1,500/mm3 ) II.Platelet count ≥ 75 × 109/L ( 75,000/mm3 ) III.Hemoglobin ≥ 9.0 g/dL IV.Prothrombin timeinternational normalize ratio partial thromboplastin time ≤ 1.5 × ULN V.Calculated creatinine clearance* ( CrCl ) 24 hour urine CrCl &gt; 50 mL/minute VI.Total bilirubin ≤ 1.5 × ULN ; subject documented/suspected Gilbert 's disease , bilirubin ≤ 3 × UL VII.AST ALT ≤ 2.5 × ULN VIII.Serum electrolytes within normal limit 11 . Female subject childbearing potential sexually active nonsterilized male partner must use least one highly effective method contraception time screening , must agree continue use precaution 90 day ( 180 day ) final dose investigational product . 12 . Nonsterilized male sexually active female partner childbearing potential must use condom plus spermicide Day 1 90 day ( 180 day ) receipt last dose investigational product . 1 . Prior treatment tumor necrosis factor receptor superfamily agonist include OX40 , CD27 , CD137 ( 41BB ) , CD357 ( GITR ) . 2 . Subjects receive prior therapy regimens contain CTLA4 , PDL1 , PD1 antagonists NOT permit enroll unless follow apply : Dose immunotherapy must administer least 28 day 5 half life , whichever short , prior plan first dose MEDI9447/MEDI4736 Must experience toxicity lead permanent discontinuation prior immunotherapy All AEs receive prior immunotherapy must resolve ≤ Grade 1 baseline prior screen study 3 . Must require use additional immunosuppression corticosteroid management AE , experience recurrence AE rechallenged , currently require maintenance dos &gt; 10 mg prednisone equivalent per day 4 . Known allergy hypersensitivity investigational product formulation 5 . History one event IRR require permanent discontinuation IV drug treatment 6 . History severe drug allergy anaphylaxis 2 food product medicine ( include know sensitivity acetaminophen/paracetamol , diphenhydramine equivalent antihistamine , methylprednisolone equivalent glucocorticoid ) 7 . Cardiac peripheral vascular disease meeting follow criterion : Past history myocardial infarction prior 12 month Past history stroke transient ischemic attack require medical therapy Congestive heart failure ≥ Class 3 base New York Heart Association Functional Classification 8 . Grade 3 great edema ( eg , peripheral , pulmonary ) 9 . History Grade 3 great thromboembolic event unresolved thromboembolic event grade 10 . Subjects active tuberculosis ineligible . In settings clinical radiographic evidence tuberculosis , active disease must rule 11 . Active prior document autoimmune inflammatory disorder ( include inflammatory bowel disease [ eg , colitis , Crohn 's disease ] , celiac disease , serious gastrointestinal chronic condition associate diarrhea , etc ) within past 3 year prior start treatment . The following exception criterion subject vitiligo alopecia hypothyroidism . 12 . Untreated central nervous system ( CNS ) metastatic disease 13 . Concurrent enrollment another clinical study , unless observational ( non interventional ) clinical study followup period interventional study 14 . Receipt conventional investigational anticancer therapy otherwise specify within 28 day prior first dose Investigational product 15 . Any concurrent chemotherapy , immunotherapy , biologic hormonal therapy cancer treatment . 16 . Unresolved toxicity prior anticancer therapy 17 . Current prior use immunosuppressive medication within 14 day prior first dose Investigational product 18 . History primary immunodeficiency , solid organ transplantation 19 . Known positive human immunodeficiency virus ( HIV ) , chronic active hepatitis B active hepatitis A C 20 . Receipt live , attenuated vaccine within 28 day prior first dose investigational product 21 . Females pregnant , lactating , intend become pregnant participation study 22 . Major surgery within 28 day prior first dose Investigational Product still recover prior surgery . 23 . Other invasive malignancy within 2 year except noninvasive malignancy cervical carcinoma situ , situ prostate cancer , nonmelanomatous carcinoma skin , ductal carcinoma situ breast surgically cure 24 . Uncontrolled intercurrent illness include , limited , ongoing active infection , active peptic ulcer disease gastritis , uncontrolled hypertension , uncontrolled diabetes , psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>101 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Solid Tumours , MEDI9447 , MEDI4736 , durvalumab , CD73 , PD-L1</keyword>
</DOC>